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Abstract
Inspired air contains a myriad of potential pathogens, pollutants and inflammatory stimuli. In the
normal lung, these pathogens are rarely problematic. This is because the epithelial lining fluid in the
lung is rich in many innate immunity proteins and peptides that provide a powerful anti-microbial
screen. These defensive proteins have anti-bacterial, anti- viral and in some cases, even anti-fungal
properties. Their antimicrobial effects are as diverse as inhibition of biofilm formation and
prevention of viral replication. The innate immunity proteins and peptides also play key
immunomodulatory roles. They are involved in many key processes such as opsonisation facilitating
phagocytosis of bacteria and viruses by macrophages and monocytes. They act as important
mediators in inflammatory pathways and are capable of binding bacterial endotoxins and CPG
motifs. They can also influence expression of adhesion molecules as well as acting as powerful anti-
oxidants and anti-proteases. Exciting new antimicrobial and immunomodulatory functions are being
elucidated for existing proteins that were previously thought to be of lesser importance. The
potential therapeutic applications of these proteins and peptides in combating infection and
preventing inflammation are the subject of ongoing research that holds much promise for the
future.
Introduction
The host response to bacterial infection of the airways is
dependent on both innate (non-antibody-mediated) and
adaptive (antibody-mediated) immune systems. The
acquired immune system is primarily cellular in composi-
tion relying on the actions of B and T cells that are pro-
longed in activation and duration. However, the innate
immune response is more immediate and depends on the
activity of phagocytic cells such as macrophages and neu-
trophils and in the expression of a number of proteins and
peptides, some of which are secreted by the respiratory
tract epithelium and phagocytic cells. The rapidity of the
innate immune system provides effective host defense
against a vast array of microbes in a manner that is inde-
pendent of prior exposure to the invading pathogen [1].
Unlike any of the other vital organs, the lung is exposed
daily to a large amount of pathogens present in air and is
potentially vulnerable to infection and inflammation. For
optimal gas exchange, the lung has a vast surface area (150
m2), a very thin delicate epithelium and extensive blood
flow. Inherent in this structure is an enormous immuno-
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Table 1: Structure, anti-microbial and immunomodulatory activities of innate immunity proteins and peptides
Protein Structure pI Pulmonary Source Antimicrobial activity Immunomodulatory activity
Lactoferrin Iron- binding 
glycoprotein MW 80 
kDa
8.7 Neutrophil secondary 
specific granules and 
submucosal gland 
epithelial cells
Bactericidal 
Bacteriostatic Inhibits 
biofilm formation Anti-
fungal Anti-viral
Binds LPS and can prevent septic shock.
Binds CPG motifs.
Anti-oxidant.
SLPI 11.7 kDA non-
glcosylated protein
>9.2 Macrophages, 
epithelial cells, 
neutrophils
Bactericidal 
Bacteriostatic Anti-viral
Powerful anti-protease Inhibits LPS-
induced NF-κB activation.
Attenuates pulmonary recruitment of 
neutrophils in sepsis models.
Impairs LTA and LPS induced 
proinflammatory gene expression in 
monocytes and macrophages.
Lysozyme 14 kDA enzyme 10.5 Neutrophil secondary 
specific granules and 
submucosal gland 
epithelial cells
Bactericidal 
Bacteriostatic
Unknown
Human 
Defensins
3–5 kDA peptides 8.8–9.5 Neutrophil azurophil 
granules and 
pulmonary epithelial 
cells
Bactericidal 
Bacteriostatic Anti-
parasitic Anti-fungal Anti-
viral
Mitogenic and chemotactic activities.
Contribute to epithelial repair in the 
lung by enhancing epithelial cell 
proliferation.
LL-37 Peptide that requires 
proteolytic processing 
to liberate the mature 
functional 
antimicrobial peptide.
Neutrophil secondary 
specific granules and 
submucosal gland 
epithelial cells
Bactericidal 
Bacteriostatic Anti-fungal 
Anti-viral
Reduced production of the pro-
inflammatory cytokine TNF-α from 
macrophages stimulated with LPS and 
may be responsible for the migration of 
immune cells to areas of inflammation 
and infection
BPI 55-kDa protein 9.6 Neutrophil primary 
granules
Bactericidal 
Bacteriostatic Act as an 
opsonin to enhance 
neutrophil phagocytosis.
Downregulates LPS and other 
endotoxins in vivo
Surfactant 
proteins A and 
D
Lipoprotein complex 4.5–5.4 Type II pneumocytes, 
airway Clara cells
Key opsonins facilitating 
phagocytosis of bactaeria 
and viruses. Bactericidal 
Bacteriostatic Anti-fungal 
Anti-viral
Both SP-A and SP-D have the capacity 
to modulate multiple leucocyte 
functions
Lactoperoxidas
e
Enzyme Airway epithelium Bactericidal Anti-fungal 
Anti-viral
CCL20 Chemokine with 
similar structure to 
HBD
Airway epithelium Bactericidal against Gram 
negative bacteria
Stimulates the migration of B-cells, 
immature dendritic cells, and a subset 
of memory T cells
logical burden. The 11,000–15,000 liters of air inhaled
daily contain a myriad of pathogens, pollutants and aller-
gens. In the normal lung, many inhaled microbes are
trapped in the mucus layer coating the nasal epithelium
and upper respiratory tract. Once trapped, they can be
transported by ciliary motion to the pharynx and swal-
lowed. For organisms that evade mucociliary clearance,
further protective immune mechanisms act locally to
facilitate clearance of inhaled pathogens and to modulate
inflammatory responses.
Organisms that reach the alveolar compartment are
deposited in the epithelial lining fluid (ELF), a thin aque-
ous film containing pulmonary surfactant that lines the
gas-exchanging surface of the pulmonary epithelium.
Whenever this deposition occurs, the invader and the host
initiate a series of complex offensive and defensive strate-
gies. Sensing of the physiologic body temperature and the
pH and ionic strength of the epithelial lining fluid (ELF)
by the organism triggers a program of gene expression
designed to optimize survival under adverse conditions.
These include up regulation of microbial genes required
for proliferation and host evasion and down regulation of
genes that regulate less necessary functions. The lung
response to this threat is coordinated by the pulmonary
epithelium and alveolar macrophages, which release
cytokines and chemokines to recruit additional inflam-
matory cells to the airspace.
In the upper respiratory tract, nasal, tracheal, and bron-
chial secretions are generated by airway epithelial cells,
especially the goblet cells; by the sub mucosal glands; by
transudation and transport of proteins from plasma; and
by resident and recruited phagocytes, neutrophils, eosi-
nophils, monocytes, and macrophages. Distally the air-
ways are lined with ELF, which is composed of airway andRespiratory Research 2006, 7:29 http://respiratory-research.com/content/7/1/29
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alveolar secretions. The composition of ELF varies by ana-
tomical location and in response to mechanical, chemical,
and microbial stimulation. In the distal airways and alve-
oli, Clara cells and type 2 alveolar cells are, respectively,
the predominant secretory epithelial cells. For the naive
host, the primary antimicrobial defences in ELF are the
resident alveolar macrophages and protein components
of the innate immune system. These intrinsic antimicro-
bial properties of respiratory secretions act in concert with
the mechanical and phagocytic clearance mechanisms to
defend the respiratory tract against colonization or inva-
sion by environmental microbes.
As first described by Alexander Fleming over 80 years ago
(Fleming, 1922), upper airway secretions contain lys-
ozyme which possesses intrinsic microbicidal and bacteri-
ostatic properties. Since these early observations, a diverse
range of antimicrobial proteins and polypeptides that are
broadly antimicrobial and predominantly cationic have
been characterised and elucidated in respiratory secre-
tions. The aim of this review is to highlight the many rolls
of the various antimicrobial proteins and polypeptides in
pulmonary innate defense.
ELF is rich in innate immunity proteins including the cell
wall-degrading enzyme lysozyme, the iron-chelating pro-
tein lactoferrin, the anti-elastase seceretory leucoprotease
inhibitor and specific membrane-permeabilizing mem-
bers of the defensin, cathelicidin, and pentraxin families.
There are a myriad of other such proteins including bacte-
ricidal permeability increasing protein (BPI), surfactant
proteins A-D and other collectins. New innate immunity
proteins are being discovered frequently and new, previ-
ously unknown defensive and immunomodulatory prop-
erties are being elucidated in existing proteins that were
previously thought to be unimportant. In the normal
lung, such proteins ensure that the process of pathogen
elimination works smoothly and seamlessly in most
cases. Antimicrobial peptides, defensins and cathelicidins,
have also been discovered which have a wide range of
microbicidal activities against Gram-positive and Gram-
negative bacteria. These peptides share some common
features including a large number of positively charged
residues and the ability to assume amphiphilic conforma-
tions such as α-helices or β-sheets. The most abundant air-
way antimicrobial factors are lysozyme, lactoferrin,
secretory leucoprotease inhibitor (SLPI), human beta
defensin peptides and the cathelicidin, LL-37 respectively
[2]. Bactericidal Permeability Increasing Protein (BPI) and
the collectins, surfactant proteins A and D also play key
antimicrobial and immunomodulatory roles. A summary
of the key innate immunity proteins is shown in Table 1.
Expression of innate immunity proteins
Expression of many antimicrobial polypeptides is modu-
lated locally by inflammation. Inflammatory stimuli
release chemoattractants that recruit neutrophils contain-
ing large amounts of antimicrobial proteins/peptides and
a number of hydrolytic enzymes. Alpha defensins, lys-
ozyme (both primary and secondary granules) and bacte-
ria permeability increasing protein (BPI) are all contained
in neutrophil primary granules from where they can be
degranulated into the phagosome thereby exposing
ingested microorganisms to high concentrations of gran-
ule contents. Secondary granules contain distinct antimi-
crobial proteins and peptides (e.g lactoferrin) which are
deployed toward the leading edge of the chemotaxing
neutrophil from where they are readily and rapidly
degranulated extracellularly [3].
Furthermore, granular contents of neutrophils can be
released into inflammatory fluids following neutrophil
death, so called "holocrine secretion" [4]. Neutrophils
engulf and kill bacteria when their antimicrobial granules
fuse with the phagosome. Zychlinsky et al have recently
described an additional neutrophil killing technique:
Activated neutrophils release granule proteins and chro-
matin that together form extracellular fibers that bind
Gram-positive and -negative bacteria. These neutrophil
extracellular traps (NETs) degrade virulence factors and
kill bacteria. NETs appear to be a form of innate response
that binds microorganisms, prevents them from spread-
ing, and ensures a high local concentration of antimicro-
bial agents to degrade virulence factors and kill bacteria
[5]. In addition to triggering release of antimicrobials
from circulating blood cells, inflammatory stimuli may
also increase the synthesis of innate immunity proteins
such as β-defensin by epithelial cells [6,7] and, when
chronic, induce the differentiation of respiratory epithe-
lial cells into secretory cell types. Lung epithelial cells and
submucosal glands have been show to express other key
innate immunity proteins including lactoferrin and LL-37
[8,9]. Lysozyme has been demonstrated in secretory gran-
ules of serous but not mucous cells in airway submucosal
glands, and was absent from the surface epithelium, carti-
lage, and connective tissue [10,11]. We shall look at some
of these defensive proteins and peptides in greater detail.
(i) Lactoferrin
Lactoferrin is an iron-binding glycoprotein (Mw 80-kDa)
and as such it exists in both iron-replete and iron-depleted
forms. The iron-depleted form of lactoferrin is its more
biologically active form. Lactoferrin is a cationic protein
with an isoelectric point (pI) of 8.7 and is widespread in
human secretions. It is found in high concentrations in
breast milk (~3–7 mg/ml), tear fluid (1–4 mg/ml), vagi-
nal secretions, gut-lining fluid, cervical mucus plugs,
saliva, exocrine secretions and respiratory secretions (0.1–Respiratory Research 2006, 7:29 http://respiratory-research.com/content/7/1/29
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1 mg/ml). Lactoferrin is released from neutrophil second-
ary (specific) granules at areas of inflammation. Like
many innate immunity proteins, lactoferrin is highly cati-
onic (calculated pI = 8.5). Lactoferrin is both antimicro-
bial and anti-inflammatory and contributes to host
defense both systemically and at mucosal surfaces. Its
antimicrobial effects include being directly bactericidal
and bacteriostatic and more recently it has been shown to
inhibit  Pseudomonas  biofilm formation by a separate
mechanism [12]. Lactoferrin exhibits antibacterial effects
on Gram-negative bacteria by means of two mechanisms.
Firstly, by binding iron, it limits the amount of free iron
(an essential growth factor for microorganisms) available.
For example, in one study Streptococcus mutans and Vibrio
cholerae were killed by incubation with purified human
apolactoferrin, the iron-depleted form of the protein.
Concentrations of lactoferrin below that necessary for
total inhibition resulted in a marked reduction in viable
colony-forming units. This bactericidal effect was contin-
gent upon the metal-chelating properties of the lactoferrin
molecule [13]. Lactoferrin contains two high-affinity fer-
ric iron binding sites facilitating such iron sequestration
from pathogenic microbes. Secondly, lactoferrin can
destabilise the outer membrane of gram-negative bacteria
by binding to it resulting in altered permeability that leads
to microbial injury and death. This activity has been
attributed to the 17 amino acid N-terminal portion of
lactoferrin. This portion is rich in arginine residues that
give the molecule its highly cationic nature and has been
termed lactoferricin. The related iron-binding protein
transferrin lacks these arginine residues and is less cationic
(pI of 5–5.5) [14]. Lactoferrin has been shown to kill clin-
ical strains of E.coli, S. aureus and mucoid P. aeruginosa
isolated from CF airways [15]. Lactoferrin acts synergisti-
cally with other innate immunity proteins such as lys-
ozyme and SLPI in bacterial killing [16,17]. It has also
been shown that lactoferrin enhances the antimicrobial
effects of some antibiotics [18]. Lactoferrin reduces the
minimum inhibitory concentration (MIC) and the mini-
mum bactericidal concentration (MBC) of doxycycline for
Burkholderia cepacia and P. aeruginosa strains with MICs for
B. cepacia falling from highly resistant to clinically achiev-
able levels [19]. By binding iron, lactoferrin can also act as
an anti-oxidant since iron bound to the protein is unable
to participate as a catalyst for the generation of free
hydroxyl radicals via the Haber-Weiss reaction [20-22].
Lactoferrin has recently been shown to inhibit Pseu-
domonas biofilm formation [12]. The inhibition of biofilm
formation is a property unique to lactoferrin and thus it
plays a pivotal role in host defense against this highly
destructive mode of bacterial growth. Biofilm bacteria are
notoriously resistant to host killing and antibiotics. They
may be up to one thousand times more resistant to anti-
biotics than their free-swimming, planktonic counterparts
[23,24]. In the presence of lactoferrin, free iron levels
decreased inducing a twitching motion in bacteria. This
twitching ensured that the bacteria wandered across a sur-
face rather than stopping to form microcolonies, clusters
and subsequent pillar and mushroom-shaped mature bio-
films. Furthermore, Singh et al demonstrated increased
susceptibility of biofilm bacteria to tobramycin in the
presence of lactoferrin. We have shown previously that
lactoferrin levels are depleted in BAL from Cystic Fibrosis
patients with active Pseudomonas infections compared to
those with no active Pseudomonas infection and that this
depletion results in impaired ability to prevent Pseu-
domonas biofilm formation [25].
Lactoferrin also has been shown to be active against a
number of viruses including human immunodeficiency
virus (HIV) and cytomegalovirus (CMV) [26,27]. Lactofer-
rin is known to prevent replication of hepatitis B and C
viruses and is being investigated clinically together with
interferon as a potential therapeutic agent in these condi-
tions [28,29]. A recent study elucidated the potential of
oral administration of lactoferrin to attenuate pneumonia
in influenza-virus-infected mice through the suppression
of infiltration of inflammatory cells in the lung [30]. In
addition to antiviral properties, lactoferrin also possesses
anti-fungal properties: it has been shown to be active
against  Candida  species and is being investigated as a
potential treatment for oral candidiasis [31].
Lactoferrin is also a key anti-inflammatory protein. It pos-
sesses two basic cradles at residues 1 to 5 and 28 to 34 of
the N-terminal end that can bind anionic molecules such
as lipopolysaccharide (LPS), heparin and heparin sulfates.
Lactoferrin has been shown to inhibit the LPS-induced
expression and proteoglycan binding ability of Inter-
leukin-8 in human endothelial cells [32]. Lactoferrin pro-
tects against sublethal doses of LPS in mice and germfree
piglets. Animals that received pre-treatment with lactofer-
rin showed minimal effects when given an intra-perito-
neal injection of LPS whereas the control group of animals
that did not receive pre-treatment with lactoferrin suc-
cumbed rapidly to septic shock [33]. Lactoferrin has also
been shown to lower the expression of adhesion mole-
cules E-selectin and ICAM-1 on endothelial cells further
modifying the immune response [34]. Another immu-
nomodulatory function of lactoferrin stems from its abil-
ity to bind unmethylated CpG motifs, which are bacterial
DNA products capable of stimulating various innate and
acquired immune responses in human and murine mod-
els [20]. A schematic of lactoferrin's many antimicrobial
and immunomodulatory roles is shown in figure 1.
(ii) Secretory Leucoprotease Inhibitor (SLPI)
SLPI is a 11.7-kDa non-glycosylated protein that is
expressed by macrophages, neutrophils and the mucosalRespiratory Research 2006, 7:29 http://respiratory-research.com/content/7/1/29
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surface of epithelial cells [35,36]. It is a highly basic (pI >
9.5), acid-stable but alkaline-labile protein [37]. SLPI is
the third most abundant innate immunity protein of res-
piratory secretions after lysozyme and lactoferrin. It is esti-
mated that SLPI is present at concentrations of 0.1 to 2 ug/
ml in airway lavage fluid [38,39] and 2.5 ug/ml in nasal
secretions[40]. SLPI through its C terminal domain is a
serine protease inhibitor and provides significant protec-
tion against neutrophil elastase, a powerful elastolytic
enzyme released from neutrophils during degranulation
at areas of infection and inflammation. SLPI also inhibits
the serine protease cathepsin G as part of its anti-protease
effects in the lung [41]. In addition to its potent anti-pro-
tease activity, SLPI has important anti-bacterial, anti-viral
and anti-inflammatory properties. The N-terminal
domain of SLPI has modest antimicrobial activity in vitro
against Gram-negative and Gram-positive bacteria [42].
SLPI has been shown to inhibit human immunodefi-
ciency virus (HIV) infectivity of monocytes by blocking
viral DNA synthesis. Saliva is rich in SLPI and it is felt that
this accounts for the low viral transmission rates via saliva
[43,44]. Prior administration of SLPI to rats attenuated
pulmonary recruitment of neutrophils in an immu-
noglobulin G (IgG) immune complex model of acute
lung injury [45]. Pre-treatment with SLPI greatly reduced
inflammation in both liver and lungs in a mouse model
of hepatic ischaemia/reperfusion injury [46]. SLPI can
inhibit LPS-induced NF-κB activation by inhibiting degra-
dation of IRAK, IκBα and IκBβ [47] and can also impair
lipoteichoic acid (LTA) and LPS induced pro-inflamma-
tory gene expression in monocytes and macrophages in
vitro [36,48]. In addition to its antiprotease activity, SLPI
has been shown to exhibit anti-inflammatory properties,
including down-regulation of tumor necrosis factor alpha
expression by lipopolysaccharide (LPS) in macrophages
and inhibition of nuclear factor (NF)-kappaB activation in
a rat model of acute lung injury. SLPI has recently been
shown to enter cells, becoming rapidly localized to the
cytoplasm and nucleus where it affects NF-kappaB activa-
tion by binding directly to NF-kappaB binding sites in a
site-specific manner [47]. However once oxidised, the
anti-inflammatory and anti-elastase effects of SLPI are
Multifunctional properties of lactoferrin Figure 1
Multifunctional properties of lactoferrin. Lactoferrin is released from neutrophils and respiratory tract epithelium and 
has multiple activities including anti-inflammatory, anti-viral, anti-lipopolysaccharide, anti-biofilm, antibacterial and anti-fungal 
properties.
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diminished. Greene et al. demonstrated cleavage of SLPI
in infected lobes in community acquire pneumonia
resulting in impaired anti-NE activity. SLPI was inacti-
vated by cleavage, oxidation and complex formation pav-
ing the way for free neutrophil elastase to exacerbate
pulmonary parenchymal inflammation and tissue dam-
age [49]. SLPI is susceptible to protease cleavage. Cathep-
sins B, L, and S have been shown to cleave and inactivate
SLPI. Analysis of epithelial lining fluid samples from indi-
viduals with emphysema indicated the presence of active
cathepsin L and cleaved SLPI [50]. Serine and cysteine
proteases produced by the house dust mite in asthma have
been shown to cleave SLPI and may increase the suscepti-
bility of patients with allergic inflammation to infection
[36].
(iii) Lysozyme
Lysozyme is a 14-kDa enzyme directed against the β 1→4
glycosidic bond between N-acetylglucosamine and N-
acetylmuramic acid residues that make up peptidoglycan,
the cell wall material that gives bacteria their shape. Lys-
ozyme is a basic protein with a pI of 10.5 [51]. It is stored
in both primary and secondary neutrophil granules. In
addition to enzymatic lysis of bacterial cell walls, lys-
ozyme can also kill bacteria by a non-enzymatic mecha-
nism [52]. Lysozyme is highly active against many Gram-
positive species, including Bacillus megaterium, Micrococcus
luteus, and many streptococci. Lysozyme also has an
important role against Gram-negative organisms. Its abil-
ity to kill Gram-negative organisms may be influenced by
ionic concentration, osmolarity, and the presence of syn-
ergistic cofactors [2,15,17].
As lactoferrin and lysozyme are present together in high
levels in mucosal secretions and neutrophil granules, it is
probable that their interaction contributes to host defense
[17]. Lactoferrin in concert with other cofactors presuma-
bly disrupt the outer membrane of Gram-negative bacte-
ria and allow lysozyme access to the sensitive
peptidoglycan layer. Lysozyme is a component of both
phagocytic and secretory granules of neutrophils and is
also produced by monocytes, macrophages, and epithelial
cells. Both lysozyme and lactoferrin arise in the lower res-
piratory tract within the airways and their levels are ele-
vated in association with chronic bronchitis suggesting
that lactoferrin and lysozyme may contribute to the mod-
ulation of airway inflammation in chronic bronchitis. Lys-
ozyme is about tenfold more abundant in the initial
"airway" aliquot than in subsequent aliquots of broncho-
alveolar lavage [53], and its concentration correlates
poorly with neutrophil concentrations, suggesting that, in
general, airway epithelium and its glands are the major
sources of lysozyme in airway secretions. Lysozyme is
present at concentrations of between 0.1 and 1 mg/ml in
respiratory secretions. In one study to assess the role of
lysozyme in pulmonary host defense in vivo, transgenic
mice expressing rat lysozyme cDNA in distal respiratory
epithelial cells were generated. Two transgenic mouse
lines were established in which the level of lysozyme pro-
tein in bronchoalveolar lavage (BAL) fluid was increased
2- or 4-fold relative to that in wild type (WT) mice. Lys-
ozyme activity in BAL was significantly increased (6.6-
and 17-fold) in 5-wk-old animals from each transgenic
line. Killing of group B streptococci was significantly
enhanced (2- and 3-fold) in the mouse transgenic lines at
6 h following infection and was accompanied by a
decrease in systemic dissemination of pathogen. Killing of
Pseudomonas aeruginosa was also enhanced in the trans-
genic lines (5- and 30-fold). Twenty-four hours after
administration of Pseudomonas aeruginosa, all transgenic
mice survived, whereas 20% of the WT mice died. The
authors concluded that increased production of lysozyme
in respiratory epithelial cells of transgenic mice enhanced
bacterial killing in the lung in vivo, and was associated
with decreased systemic dissemination of pathogen and
increased survival following infection [54]. A recent in vivo
study of lysozyme derived from submucosal glands in fer-
ret trachea demonstrated that lysozyme-depleted secre-
tions were much less effective at inhibiting bacterial
growth than mock-depleted samples, suggesting that lys-
ozyme is partially responsible for the antibacterial activity
of the glandular airway secretions. Furthermore, depletion
of lysozyme from human nasal secretions also reduced
antibacterial activity by 50% [55].
(iv) Defensins
Defensins are 3- to 5-kDa peptide members of a widely
distributed family with characteristic three-dimensional
folding with six cysteine-three disulfide patterns.
Defensins have broad cytotoxic activity against bacteria,
fungi, parasites, viruses and even host cells [56].
Defensins are subdivided into different classes that
include alpha and beta defensins. Alpha defensins are also
known as human neutrophil peptides (HNPs). HNP-1 to
-4 are found in azurophil granules of neutrophils where
they constitute up to 50% of the total protein present [57].
HNP-5 and -6 have been identified in Paneth cells in the
crypts of the small intestinal mucosa and also in the
female reproductive tract. The alpha defensins have a wide
variety of actions including mitogenic and chemotactic
activities [58,59]. Alpha defensins contribute to epithelial
repair in the lung by enhancing epithelial cell prolifera-
tion [60]. The more recently identified human beta
defensins (HBDs) 1–4 differ slightly from classical alpha
defensins in the spacing and connectivity of their
cysteines [2]. Beta defensins have five to eight positively
charged residues resulting in quite similar (calculated)
isoelectric points of 8.9 to 9.5 [61]. HBD-2 and -3 are
secreted in response to LPS and cytokines (TNFα, inter-
leukin-1 beta) and are active against Gram-positive (HBD-Respiratory Research 2006, 7:29 http://respiratory-research.com/content/7/1/29
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3) and Gram-negative (HBD-1, -2 and -3) bacteria whilst
HBD-1 is upregulated by interferon-gamma (IFN-γ) [62-
64]. We have previously demonstrated that human lung
epithelial cells express Toll-like receptor four (TLR4) on
their surface and that stimulation of these cells with Pseu-
domonas LPS results in increased HBD2 gene and protein
expression [65]. All three beta defensins have been identi-
fied in lung and they have been shown to act synergisti-
cally with other innate immunity proteins in bacterial
killing [15]. Individual beta defensins have differential
antimicrobial activity. Staphylococcus aureus is resistant to
killing by HBD-1 and HBD-2 but even strains of this
organism that are multi-drug resistant are susceptible and
sensitive to killing by HBD-3 [66]. We have shown previ-
ously that HBD 2 and 3 are susceptible to proteolytic
cleavage by cysteinyl cathepsins that are present at ele-
vated concentrations in the Cystic Fibrosis and COPD air-
ways [49]. New families of defensins and individual
defensins are being discovered. A novel family of antimi-
crobial peptides termed "theta defensins" has been
described in monocytes and macrophages of macaque
monkeys. Theta defensins are naturally produced by a
unique ligation of two truncated alpha defensins [67].
Whilst they are important in their own right, β-defensins
are present at much lower concentrations than lysozyme,
SLPI or lactoferrin and thus their overall contribution to
host defense must be taken in context [15].
(v) Cathelicidin LL 37
Cathelicidins are a family of antimicrobial proteins found
in neutrophil specific granules of which LL-37 is the only
human member identified to date [9,68,69]. LL-37 is also
present in certain lymphocytes, testicular tissue and air-
way epithelium [9,68]. Cathelicidins are stored as inactive
pro-peptides precursors and require processing to become
active peptides [70]. LL-37 is activated when proteinase 3
cleaves its precursor, hCAP-18. Some cathelicidin genes
possess upstream DNA motifs (eg. NF-κB) predicted to
convey inducibility during acute phase responses [71]. LL-
37 has been shown to reduce bacterial load by Pseu-
domonas when over-expressed in murine models [72]. Fur-
thermore it conveys improved survival following
administration of lethal doses of LPS [72]. LL-37 also
reduced production of the pro-inflammatory cytokine
TNF-α from macrophages stimulated with LPS and may
be responsible for the migration of immune cells to areas
of inflammation and infection [73]. Protegrin, the por-
cine equivalent of LL-37 is currently being evaluated as an
anti-inflammatory/antimicrobial agent in patients with
mucositis post chemotherapy [3]. LL-37 activity may be
impaired in Cystic Fibrosis where anionic filaments of F-
actin and DNA bind to it and inhibit its bactericidal
action. Addition of the actin filament-fragmenting protein
gelsolin frees LL-37 from this binding and restores antimi-
crobial activity [72].
(vi) Bactericidal Permeability-Increasing protein (BPI)
BPI is a 55-kDa protein that is predominantly active
against Gram-negative bacteria [2,74]. It is stored in neu-
trophil primary granules and exerts its effects through
three distinct mechanisms: firstly, it is directly cytotoxic
via its effects on bacterial membranes; secondly, it acts as
an opsonin to enhance neutrophil phagocytosis and
thirdly, it can neutralise bacterial LPS [75]. In common
with many innate immunity proteins, BPI possesses a
highly cationic N-terminal end which contains its bacteri-
cidal and endotoxin neutralising zones [75,76]. As with
many of these defensive proteins, BPI acts synergistically
with other members of the innate immune system such as
cathelicidins and defensins in bacterial killing. It also acts
in concert with the complement system [76]. BPI is
thought to have a role in down-regulating the pro-inflam-
matory effects of gram-negative bacteria and endotoxins
in vivo [77].
(vii) Collectins - Surfactant Proteins A and D
Pulmonary surfactant is a lipoprotein complex that is syn-
thesised by type II pneumocytes and by airway Clara cells.
It is secreted into the epithelial lining fluid where it mod-
ulates surface tension. More recently surfactant has been
shown to play a role in host defense against infection and
inflammation. Surfactant proteins belong to the collagen-
like-lectin or collectin family that also includes mannose
binding protein bovine coglutinin and CL-43 [78,79].
Collectins share an N-terminal collagen-like domain and
a C-terminal lectin or Carbohydrate recognition domain
(CRD) domain capable of binding carbohydrates in a cal-
cium-dependent manner. These C-type lectin domains
can bind oligosaccharides found on bacterial, non-encap-
sulated fungal as well as viral envelope surfaces [79]. Sur-
factant consists of the four surfactant proteins 1–4 bound
to phospholipids and is responsible for reducing surface
tension at the air liquid interface within the alveoli in
lung. Surfactant proteins are key opsonins facilitating
phagocytosis of bacteria and viruses by macrophages and
monocytes [80] Both SP-A and SP-D have been shown to
be directly bactericidal against E.coli, while SP-A and SP-D
are fungicidal against Histoplasma Capsulatum. SP-A and D
deficient mice were unable to kill this fungus [81]. Both
SP-A and SP-D have the capacity to modulate multiple
leucocyte functions [78,82]. The addition of SP-A to cul-
tures of Mycoplasma. pneumoniae markedly attenuated the
growth of the organism assessed by colony formation,
metabolic activity, and DNA replication. The bacterio-
static effects of SP-A were reversed by dipalmitoylphos-
phatidylglycerol. These findings demonstrate that human
SP-A can play a direct role in antibody-independent
immunity to M. pneumoniae by interacting with lipid lig-
ands expressed on the surface of the organism and impli-
cate SP-A in the immediate host response to the bacteria
[83].Respiratory Research 2006, 7:29 http://respiratory-research.com/content/7/1/29
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Recent research has focused on the proteolytic cleavage of
SP-A and D by various proteases in the lung. Proteolytic
damage to surfactant protein by neutrophil elastase and
cathepsin G was demonstrated in bronchoalveolar lavage
fluid of cystic fibrosis patients [84]. The bacterial protease,
Pseudomonas aeruginosa elastase was shown to degrade SP-
A and SP-D [85]. Furthermore, cleavage of SP-D by this
enzyme results in failure of the surfactant to bind or aggre-
gate bacteria that are aggregated by intact SP-D. Thus,
cleavage eliminates many of SP-D's normal immune func-
tions [86].
(viii) Lactoperoxidase
Early animal studies showed airway mucosa secretes an
enzyme known as peroxidase that was active in preventing
infection of the airway[87]. Gerson et al subsequently
demonstrated production of the biocidal compound
hypothiocyanite in vitro by airway lactoperoxidase (LPO).
They also showed in vivo inhibition of airway LPO in
sheep leads to a significant decrease in bacterial clearance
from the airways. Their data suggest that the LPO system
is a major contributor to airway defenses [88]. The airway
LPO system may provide additional protection against
viral [89-91] and fungal infections [92,93]. LPO was sub-
sequently demonstrated in human airways airway secre-
tions with activity against Pseudomonas aeruginosa,
Burkholderia cepacia and Haemophilus influenzae [94].
(ix) CCL20
Chemokine ligand 20 (CCL20) shares similar structural
and functional properties with human beta-defensins
(HBDs) Airway epithelial cells have been shown to
express CCL20 [95]. The inflammatory cytokines inter-
leukin (IL)-1β and tumor necrosis factor-α (TNF-α)
upregulate expression of this protein via the nuclear factor
(NF)-κB pathway [96,97]. CCL20 is also produced by
neutrophils [98]. It has been shown to exert antimicrobial
activity against a wide spectrum of mainly Gram-negative
bacteria [99]. Starner et al demonstrated that CF BAL con-
tains elevated concentrations of CCL20 compared to nor-
mal BAL and that CCL20 exhibited salt-sensitive
bactericidal activity [95].
Potential therapeutic applications
The use of antimicrobial peptides and proteins as poten-
tial therapeutic targets is an attractive concept. Theoreti-
cally, such compounds would have low immunogenicity
and high bioavailability with minimal toxicity [2]. The
costs involved in developing, producing and administer-
ing such compounds should be outweighed by the enor-
mous potential benefits in an era where antibiotic
resistant has reached crisis proportions. Gene therapy as a
means of augmenting levels of active antimicrobial pro-
teins (cathelicidins) was previously investigated [72]
although there has been little progression in developing
this early work. Alternatively, innate immunity proteins
such as lactoferrin could potentially be aerosolized
directly into the lungs in CF as is currently being evaluated
with protegrin, a porcine-derived cathelicidin [3]. Recom-
binant human lactoferrin (rHLF) is relatively cheap to
manufacture and of low antigenic potential. Inhaled rHLF
has been shown to reduce the late phase response to anti-
genic stimuli in sheep [100]. It has been shown to be safe
in a phase II clinical trial based on its immunomodulatory
effects in asthma in humans [101]. Another strategy could
involve protecting native antimicrobials from proteolytic
degradation by proteases. Surfactant proteins are suscepti-
ble to protease cleavage by bacteria-derived proteases
[86]. We have shown previously that lactoferrin [25], SLPI
[50] and human β-Defensins [49] are all rapidly degraded
by cysteinyl cathepsins that are over-expressed in chronic
lung diseaes such as Cystic Fibrosis and COPD. Cleavage
of innate immunity proteins results in loss of their antimi-
crobial effects. Cystatins are naturally occurring cathepsin
inhibitors that appear to be overwhelmed by the sheer
cathepsin burden in these conditions. Design of a selec-
tive pharmaceutical cathepsin inhibitor based on cystatins
or small synthetic cathepsin inhibitors could minimize
cleavage of these innate immunity proteins, thereby opti-
mizing the pulmonary antimicrobial screen. Perhaps the
ideal combination would be a nebulised innate immunity
protein (eg lactoferrin) to augment depleted natural levels
coupled with a synthetic cathepsin inhibitor to prevent
proteolytic degradation. Implementation of such a regime
early in CF before biofilms have taken hold could poten-
tially reduce morbidity and mortality from P. aeruginosa
infections in CF significantly. Strategies to inhibit innate
immunity protein cleavage by other proteases such as NE
and bacterial proteases may also have therapeutic poten-
tial. The emergence of widespread resistance to many con-
ventional antibiotics and the selecting out of multi-drug
resistant "super-bugs" should prompt further investiga-
tion into potential roles for innate immunity proteins in
the clinical arena. Synergistic combinations of innate
immunity proteins with existing antibacterial and anti-
fungal agents should continue to be evaluated [102].
Conclusion
Microbes are capable of rapid adaptation to changing
environmental conditions to maximise survival and
increase pathogenicity. Species diversity and genetic heter-
ogeneity lead to multiple virulence factors among micro-
organisms in the respiratory tract. In order to combat this
threat, the lung is endowed with incredibly powerful and
potent antimicrobial and anti-inflammatory proteins that
also have rolls in epithelial repair. Despite recent advances
in our knowledge of the complex roles and functions of
the various innate immunity proteins in pulmonary infec-
tion and inflammation, further research is needed to char-
acterize and elucidate specific biological functions andRespiratory Research 2006, 7:29 http://respiratory-research.com/content/7/1/29
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pathways of individual proteins. Strategies to augment
innate immunity proteins or to prevent their degradation
may provide future therapeutic options. As our under-
standing of this key area grows, we must learn to harness
these "natural born killers" and derive maximum clinical
benefit from them.
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